Advertisement

U.S. markets closed

S&P Futures
4,477.75
+30.75(+0.69%)
Dow Futures
34,566.00
+44.00(+0.13%)
Nasdaq Futures
15,384.00
+188.50(+1.24%)
Russell 2000 Futures
1,879.30
+4.10(+0.22%)
Crude Oil
78.52
-0.37(-0.47%)
Gold
1,948.40
+0.30(+0.02%)

Advertisement

Carisma Therapeutics, Inc. (CARM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

6.62

-0.12

(-1.78%)

At close: 04:00PM EDT

6.55

-0.07

(-1.06%)

After hours:

06:01PM EDT

Advertisement

Trade prices are not sourced from all markets

All

Zacks
Wall Street Analysts Predict a 48.37% Upside in Carisma Therapeutics Inc. (CARM): Here's What You Should Know
The mean of analysts' price targets for Carisma Therapeutics Inc. (CARM) points to a 48.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Simply Wall St.
Carisma Therapeutics Second Quarter 2023 Earnings: Beats Expectations
Carisma Therapeutics ( NASDAQ:CARM ) Second Quarter 2023 Results Key Financial Results Revenue: US$3.56m (up 32% from...
PR Newswire
Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended June 30, 2023, and highlighted recent business updates.